- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Opioid dependence
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1265KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 125KB)
Buprenorphine – November 2021
Buprenorphine: Injection (modified release) 8 mg in 0.16 mL pre-filled syringe, Injection (modified release) 16 mg in 0.32 mL pre-filled syringe, Injection (modified release) 24 mg in 0.48 mL pre-filled syringe, Injection (modified release) 32 mg in 0.64 mL pre-filled syringe; Buvidal® Weekly; Injection (modified release) 64 mg in 0.18 mL pre-filled syringe, Injection (modified release) 96 mg in 0.27 mL pre-filled syringe, Injection (modified release) 128 mg in 0.36 mL pre-filled syringe, Injection (modified release) 160 mg in 0.45 mL pre-filled syringe; Buvidal® Monthly
